. (2002) Transport and metabolism of opioid peptides across BeWo Cells, an in vitro model of the placental barrier. Int. J. Pharm. 233,[85][86][87][88][89][90][91][92][93][94][95][96][97][98] Abstract: In keeping with the advance of biotechnology, cell culture becomes an important tool for investigating the transport and the metabolism phenomena. A cell line of human origin, the BeWo choriocarcinoma cell line, was used for the study of the transport and metabolism of opioid peptides across the in vitro model of the placental barrier. Opioid peptides, both naturally occurring and their synthetic analogs, are of interest to be developed as potent analgesics and were included in this study. The apparent permeability coefficients of the peptides containing 4 to 11 amino acid or analog residues were in the range of 0.23-14.60 x 10 -5 cm/sec. The apparent permeability coefficients of these peptides were comparable to those of sucrose or dextrans, hydrophilic markers. Molecular weight and size of the peptides were inversely correlated to the permeability across the BeWo monolayers. Lipophilicity and charges of the peptides were also investigated and found to be the minor factors regulating the extent of peptide permeation. Contrasting to the transport of DPDPE peptide analog across the blood-brain barrier, the transport of DPDPE across the BeWo monolayers were not found to be via carrier-mediated transport. The major transport pathway of the opioid peptides across the BeWo monolayers was found to be via paracellular route. In metabolism studies, aminopeptidase was found to be a major enzyme type responsible for the degradation of naturally occurring peptides but not for the synthetic analogues. The finding obtained from the present study reveal the applicability of the BeWo cell line to be used as the in vitro cell culture model for the transport and metabolism screening of the opioid peptides.
Introduction
Since the discovery of multiple opioid receptors (1) and endogenous opioid peptides (2), several attempts have been made to synthesize safe and effective agonists to selective opioid receptors. The clinically used µ-opioid receptor agonists such as morphine and meperidine are associated with side effects, which range from constipation to respiratory depression and dependence liability (3) . In addition, the above mentioned µ-receptor agonists have the ability to rapidly cross the placental barrier, thus posing a risk to the developing fetus.
The developing fetus is not known to express the δ-opioid receptor (4) .
Therefore, selective δ-opioid receptor analogues can be developed without the risk of any adverse effects to the fetus. The endogenous δ-opioid receptor-specific enkephalins (leu and met-enkephalins) have been shown to have significant analgesic properties (2).
However, due to their high susceptibility to enzymatic degradation in vivo, attempts are being made to synthesize highly selective, enzymatically stable analogues of enkephalins which can be clinically used in the treatment of pain. Mosberg et al. (5) reported the synthesis of several synthetic analogues of leu-enkephalin with high selectivity towards the δ-opioid receptor. In addition, some of these peptides have shown good in vivo stability and appear to be promising candidates for the treatment of pain (6) . The bloodbrain barrier (BBB) transport of one synthetic analogue of leu-enkephalin, DPDPE, was found to be carrier-mediated (7) . However, no information currently exists on the placental transport and metabolism of these peptides. 4 The primary function of the placenta is to transport nutrients and excretory products to and from the fetus. In addition, the placenta is also involved in the synthesis of hormones and steroids (8) . Although passive diffusion is the principal mechanism of transport across the placenta (9) , several carrier-mediated transport mechanisms (e.g. for glucose, fatty acids and amino acids) have been identified (10, 11) . Several in vivo and in vitro models have been utilized to study the transport of substances across the placental barrier (12, 13) . However, in vitro models provide a simple and rapid method of studying the mechanistic aspects of drug transport. Several cell lines (e.g. JAR, JEG and BeWo) have been evaluated for their potential applications in the study of the mechanisms of trans-trophoblast transport of drugs (14) (15) (16) . The BeWo cell line is a choriocarcinoma cell line developed from a malignant gestational choriocarcinoma of the fetal placenta and was characterized in 1968 (17) . This cell line has been shown to exhibit morphological and biochemical characteristics, similar to the human trophoblasts and the presence of nutrient and serotonin transporters (18) (19) (20) . In addition, the BeWo cell line is stable, easy to maintain by passage and forms confluent monolayers on polycarbonate filters in a relatively short period of time (4-5 days), making it an attractive in vitro model to study trans-trophoblast transport, uptake and metabolism of drugs.
Peptide transport across the placenta has not been studied extensively. Of the few reported studies, the primary mechanism of peptide transport across the placenta appears to be via paracellular diffusion (21) . However, a low affinity transporter for dipeptides has been shown to exist (22) . The objectives of the present work were to investigate the trans-trophoblast transport of a series of opioid peptides and to determine the effect of physico-chemical properties (molecular size, molecular weight and lipophilicity) on their 5 transport across the trophoblast barrier. In addition, the susceptibility of the peptides to enzymatic degradation and the mechanisms of transport of one synthetic analogue (DPDPE) across the trophoblast monolayers were also investigated.
Materials and Methods

Materials:
Translucent polycarbonate filters (12 mm diameter, 0.4 µM pore size) were obtained from Fisher Scientific. (IMNDA), a fluorogenic derivatizing reagent, was synthesized in our laboratory. Sodium cyanide (NaCN) was purchased from Aldrich (St. Louis, MO). All other chemicals were of the highest, commercially available grade.
BeWo cell culture:
The BeWo clone (b30) was obtained from Dr. Alan Schwartz (Washington University, St. Louis, MO). The cells were cultured and harvested as previously described (23) . For transport studies, the cells were passed onto polycarbonate membranes coated with rat tail collagen. At a seeding density of 100,000 cells/cm 2 , the cells formed monolayers in 4-5 days. The medium was changed every other day and all cells used for these studies were from passages 35-90.
Transmonolayer Permeability:
Trans-monolayer permeability studies were carried out using a Side-Bi-Side diffusion apparatus (Crown Glass Company). The donor and receiver chambers were each filled with 3.0 ml of PBSA (pH 7.4). The cells faced the donor chamber as the apical (maternal) side and the membranes faced the receiver chamber as the basolateral (fetal) side. The temperature during the studies was maintained at 37°C using thermostated water jacket. 
Where P is the apparent permeability coefficient, X is the amount of substance (mol) in the receiver chamber at time t (s), A is the diffusion area (0.636 cm 2 ) and C d is the concentration of the substance in the donor chamber (mol/cm 3 ). The permeability coefficients were expressed as the mean ± SD from three to six different monolayers.
The apparent permeability coefficients for the BeWo monolayers , P e , were calculated from the following relationship;
1/P t = 1/P c + 1/P e where P t is the apparent permeability coefficients for the collagen-coated polycarbonate membranes in the presence of BeWo cell monolayers and P c is the apparent permeability coefficients for collagen-coated polycarbonate membranes alone (24) .
In order to determine the mechanism of DPDPE transport across the BeWo monolayers, transport experiments (n = 4-6) of 5 nM 3 H-DPDPE were carried out in the presence of excess (300 µM) unlabelled DPDPE. In addition, to ensure that DPDPE was 
Stability of Opioid Peptides upon Exposure to the BeWo Monolayers:
The BeWo cells were seeded at 100,000 cells/cm 2 into the 12 well tissue culture plates. Collagen-coated polycarbonate membranes were not required in this study. Cell maintenance was performed as described earlier; however, care was taken due to an easier detachment of the cell membranes from the plastic surface than the surface of the collagen-coated polycarbonate filters. Since fully-grown or aged cells will detach easily from the plastic surface, the metabolism study was performed after the cells had grown to cover about 90% of the total surface. The cell monolayers were washed 3 times with 37°C phosphate buffer saline-ascorbic acid (PBSA) solution to eliminate other primary amines such as amino acids in cell culture media or other peptides that cells might have released to the medium. Subsequently, the tissue culture plates were incubated in a temperature-controlled shaking water-bath (60 rpm, 37°C) for 10 minutes.
Afterward, a peptide solution (25.0 µM) was added to each well including control wells, the wells without BeWo cell monolayers present. Immediately after the addition of the peptide solution, peptide aliquots were withdrawn for the initial concentration 10 determination. At 5, 15, 30, and 60 minutes, 176 µl aliquots were pipetted out from the subsequent wells. The samples were collected in polypropylene vials and were then frozen immediately until the analysis.
Lipophilicity:
Utilization of the capacity factor (k´) from reversed-phase high-performance chromatography (RP-HPLC) has been reported for lipophilicity measurement (26, 27) .
In this study, the relative lipophilicity of the opioid peptides was determined from the ability of the peptides to interact with the immobilized artificial membrane (IAM). An IAM chromatography column (4.6mm i.d. x 100 mm, 5 µm, 300 Å, Regis Technologies, Inc., Morton Grove, IL) with 5-10% ACN in 10 mM phosphate buffer as a mobile phase was used in determining of the ability of the peptides to interact with phosphatidylcholine (PC) analog membranes. The PC analog membranes are the artificial membrane mimic the lipid environment found in cell membrane (28, 29) . A 20 µl aliquot of each peptide solution (100 µM) was injected on the column (flow rate 1.0 ml/min), and the eluate was detected with the UV (210 nm) detector (Shimadzu, Columbia, MD). The IAM capacity factors (k′ IAM ) of the opioid peptides were calculated from the following equation:
where t R is the retention time of a peptide and t 0 is the column void volume. Permeability coefficients were plotted against the k′ IAM of the opioid peptides in order to evaluate the relationship between the relative lipophilicity of the peptides and ability to cross the BeWo monolayers. Although very few studies have been conducted, peptide transport across the placenta appears to be primarily via passive diffusion (21) . The placenta, unlike the gastro-intestinal or the blood-brain barrier is a 'leaky' barrier and allows for a relatively free exchange of substances. The apparent permeability coefficients of most of the peptides studied (Table 1) 
Lipophilicity vs. Permeability Coefficients:
Lipophilicity is another parameter that was investigated. Immobilized artificial membrane (IAM) chromatography was selected to investigate the relative lipophilicity of the peptides. IAM chromatography was employed for the evaluation of lipophilicity and analytes. This finding suggests that the transport mechanism via transcellular route is not a major pathway for the permeation of peptides across the BeWo monolayers.
As the peptides included in our study are relatively hydrophilic and their P e (s) are comparable to those hydrophilic markers, restricted diffusion through water-filled transmembrane channels or pores which is a primary transport mechanism of most hydrophilic substances was suggested to be a major transport mechanism for these peptides. In general, water-soluble drugs with molecular weights below 800 daltons (37) and perhaps closer to 1000 daltons (21, 38) appear to passively diffuse across the human placenta. Similarly, the peptides included in our study whose molecular weights are higher than 1000, such as dynorphin A (1-11), (2-11) and (1-8), encountered some permeability difficulties due to a sieving property of the membrane. These observations implied that the BeWo cell monolayers described by Liu et al. (23) are likely to have similar permeability properties, such as pore size and porosity, to the human placental membrane.
Due to the hydrophilic nature of these peptides, it is unlikely for them to be transported via a transcellular mechanism. However, additional experiments were carried out to determine whether a carrier-mediated mechanism exists in the trans-trophoblast transport of the opioid peptides. Williams et al. (7) reported the presence of a saturable transport system involved in the BBB transport of DPDPE. Therefore studies were initiated to determine the trans-trophoblast transport of DPDPE using the in vitro cell culture model. The placenta is known to have significant amounts of peptidase activity (39, 40). Although DPDPE has been shown to be stable against enzymatic degradation, 16 the transport of 3 H-DPDPE was studied in the presence of amastatin (50 µM). As seen from the data (Figure 5 ), the permeability coefficients of 3 H-DPDPE were not influenced by the presence of an excess amount (300 µM) of unlabelled DPDPE or amastatin [(p<0.05) from 3 H-DPDPE alone]. These studies show that DPDPE is resistant to enzymatic hydrolysis by the placenta and it's primary mechanism of transport across the placenta is via passive diffusion.
Although a number of observations had been reported about the transport systems of nutrients and electrolytes across the placenta (37, 41) , very limited information is available on peptide transport. To date, one uptake study reported on the presence of very low affinity dipeptide transporter(s) found in brush-border membrane vesicles (BBMV) prepared from human full-term placenta (22) . However, these peptide transporters were not responsible for peptide uptake into human placental BBMV. A simple diffusion mechanism was also suggested to be a transport pathway of oxytocin from the study using in vitro dually perfused isolated cotyledons from term human placenta (21) . While the other types of transport mechanisms remain unclear, an observation from our study suggested a possibility of the peptide transport via a transcellular route. For all of the peptides included in this study, less than ten percent of the total amount of the peptides were observed in the receiver chambers. Unlike other hydrophilic peptides, the permeation of rather lipophilic peptides, TIPP-ψ and TIPP, was observed with the lag-times of 5 and 30 minutes for TIPP-ψ and TIPP permeation, respectively. From mass balance consideration, the recovery of most peptides was approximately one hundred percent; except for TIPP. About 18% of TIPP were lost from the initial amount. These observations suggested that a partial amount of TIPP could 17 remain adhered to the membrane and/or in the cells, implying that the transcellular transport could be a pathway for relatively hydrophobic peptides, such as TIPP in this case.
Berhe et al. (42) reported the importance of charge effects on the permeability of positive or negative horseradish peroxidase across guinea-pig placenta. Positively charged protein was found to permeate across the placenta better than the negatively charged protein. However, no relationship between the charges and the permeability coefficients for the peptides was observed in this study. Therefore, the changes of maternal and fetal plasma pH would not be expected to affect the permeability of these peptides.
Stability of Opioid Peptides upon Exposure to BeWo Cell Monolayers:
Aminopeptidases, carboxypeptidases, endopeptidases and dipeptidases were previously reported to be the enzymes responsible for degrading peptides in the human placenta. Widely distributed in different parts of the placental cells, the transports of both naturally occurring and synthetic peptides are largely inhibited by peptidases (39, 40, 43) .
In this study, the naturally occurring opioid peptides, leu-enkephalin, dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) and the synthetic peptides, DADLE, TIPP and TIPP-ψ, were incubated with the BeWo cell monolayers at 37°C. The surface area of a 12-well plate used in the metabolism study was larger than the surface area of Side-Bi-Side diffusion unit, and the degradation of the naturally occurring peptides became significant. In the case of LE, although more than one site of the peptide bonds of LE is vulnerable to the enzymatic degradation, the major metabolite observed on the chromatogram was identified to be 18 des-Tyr-leu-enkephalin. Des-Tyr-leu-enkephalin was also a primary metabolite of leuenkephalin found in rat jejunum (44) and in brain microvessel endothelial cells (BMEC) (45) . Rapid degradation was also observed for the dynorphin A (1-11), another naturally occuring opioid peptide ( Figure 6 ). The half-life of the intact dynorphin A (1-11) was
found to be about 15 minutes. The presence of aminopeptidases in the BeWo cells was also confirmed in this study. The dynorphin A (1-11) was rapidly converted to several small fragments including des-Tyr peptide [dynorphin A (2-11)], which was the major identifiable metabolite. The dynorphin A (2-11) was subsequently metabolized to other unidentified fragments. Contrasting to the observation in plasma, dynorphin A (1-13)
were 80% metabolized by carboxypeptidases (46) , yielding dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . In this study, dynorphin A (1-10) was found to be insignificant amounts upon the exposure of dynorphin A (1-11) to the BeWo cells, suggesting that aminopeptidases are the major enzymes in this cell type. The peptidase activity in the BeWo cells was reported to be comparable to the activity in the placental cells from the primary cultures of the human cytotrophoblasts, however; the presence of gestation time, environment, smoking habits, drugs, metal and hormonal factors were shown to be important to the activity of the peptidases (40, 43) . In contrast to the naturally occurring peptide counterparts, the synthetic peptides, DADLE, TIPP and TIPP-ψ, were more stable upon incubation with the BeWo cells ( Figure 7) . Therefore, the incorporation of unnatural amino acid residues into the peptide structures gave the peptides more resistance to placental enzyme degradation. However, awareness should be made when the chemical modification of the peptide structure was adopted, since the ability of peptides to bind with opioid receptors is highly dependent on peptide stereochemistry (47) . The introduction of D-amino acid Leu-Enkephalin; DADLE; Dynorphin A (1-11)
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